Kane Akai
Analyst
Shardin
Equibles does not estimate personal net worth.
About Kane Akai
Kane Akai is recorded as Analyst at Shardin. Kane Akai has spoken on 1 investor event across 1 company, most recently for Coya Therapeutics, Inc. on October 20, 2026. The companies whose calls Kane Akai spoke on are classified in the Healthcare sector.
Kane Akai on recent calls
“In this one, we want to kind of continue our discussion on neurodegenerative diseases. In this session, we're going to focus on ALS. My name is Kane Akai. I'm the Director of Research and one of the Senior Biotech Analysts at Shardin.”
Affiliation history
-
Shardin
Analyst
Transcript header (unverified)
Current